Care Atlas

CMS Open Payments · 2024

Dr. Hakan Kaya

Medical Oncology · SPOKANE, WA · NPI 1255320974

Many doctors share a name — check the specialty and city above match your doctor before you read this as theirs.

$420,032 reported by drug & device companies in 2024 · 324 payments

Not all payments mean the same thing. Split apart:

$420,032
Promotional

Meals, speaking fees, travel, consulting — money from companies marketing their products. This is the relationship to weigh against a recommendation. For this doctor it is substantial.

$0
Royalty / ownership

Income for a device or method the doctor invented or owns — large for some surgeons, and not a conflict over what to prescribe you.

This is well above what most doctors receive in promotional payments — a relationship worth being aware of when weighing a recommendation.

Largest paying companies

The companies that paid this doctor the most in 2024 — each company's full total (promotional + research + royalty), from CMS's separate by-company report, so these may not add up to the split above.

Takeda Pharmaceuticals U.S.A., Inc. $79,128
BeiGene USA, Inc. $74,367
Pfizer Inc. $65,458
Karyopharm Therapeutics Inc. $54,164
Genzyme Corporation $44,291

What the payments were for

Speaking / services (non-CE) $295,398Travel & lodging $63,194Honoraria $47,500Consulting fees $7,175Food & beverage $6,623Education $143

What this is — and is not

This is the public record companies are required by law to report (the Sunshine Act). A disclosed payment is a financial relationship — it is not proof of wrongdoing, and not evidence that it changed your care. Many payments are entirely legitimate (research, royalties for inventions, education). The point is transparency: you get to know, and to ask. It is not a rating of Dr. Hakan Kaya.

Also available: structured data · plain text. Verify at CMS Open Payments (NPI 1255320974).